Good morning %%first_name%% %%last_name%% Monday, April 4, 2016

Leading The News

Advertisement
Advertisement

Study Finds Statins To Be Most Effective Therapy To Prevent Heart Problems In Patients Without Heart Disease.

The AP (4/3) reports research “published online Saturday in the New England Journal of Medicine and presented at an American College of Cardiology meeting in Chicago,” that found statins “can prevent heart attacks and strokes in a globally diverse group of older people who don’t have heart disease.” The global study took place in 21 countries and treated participants with either statins, blood pressure medications, or both. The study results found statins to be the most effective at preventing heart problems.

Patient Care And Prevention

BMI In Infancy May Predict Which Children Are Likely To Be Obese At Age 6.

CBS News (4/1) reports on its website that “pediatricians usually start monitoring kids for obesity risk at a 2-year-old’s well-child visit, but” research presented at the Endocrine Society meeting “shows severe obesity is predictable as early as six months old. The authors recommend children start being screened for the condition as babies.” Investigators “analyzed electronic records of children under the age of 6, including 783 lean children and 480 severely obese children.” The researchers found that “the body mass index ratings in children who become severely obese by age 6 began to differ from children who remain normal weight as early as 4 months of age.”

Evolocumab May Benefit Patients With Statin Intolerance.

The Washington Post (4/3) reports that research “shows for the first time that statin intolerance is very real and that a newer, different kind of drug can have a strong impact on these patients’ high cholesterol.” Investigators “found that 42.6 percent of people who had complained of muscle pain while taking at least two different statins experienced the same symptoms when given a statin during the study but had no ill effects when administered a placebo.” According to the Post, “They were then able to reduce their LDL cholesterol levels by more than half when given a PCSK9 inhibitor, evolocumab, for 24 weeks, compared with just a 16.7 percent reduction on ezetimibe, another medication.” The findings were presented at the American College of Cardiology meeting and published in JAMA.

“Strong Scientific Consensus” That Zika Is Linked To Microcephaly, WHO Says.

USA Today (4/1) reported that on Friday, CDC Director Thomas Frieden said “the nation’s highest priority should be to protect pregnant women and their fetuses,” and added that Zika is “now strongly linked to ‘catastrophic’ birth defects, including microcephaly, in which babies are born with abnormally small heads.”

        The New York Times (4/1, Subscription Publication) reported that on Thursday, the World Health Organization said “there is ‘strong scientific consensus’ that Zika virus is a cause of microcephaly.” However, the Times pointed out that while the Zika virus has spread throughout South America and Latin America, “a surge in microcephaly has been reported only in Brazil.”

Subscriber Tools

     • Change Email Address
     • Send Feedback
     • Unsubscribe
     • Email Help
Advertise with BulletinHealthcare: Reach key professionals every morning

The Morning Brief is a digest of the most important news selected from thousands of sources by the editors of BulletinHealthcare and delivered digitally to members of the American Osteopathic Association (AOA). This is provided to members solely as information that may be of interest. The AOA does not endorse these articles, nor views expressed therein. Neither the AOA nor BulletinHealthcare is responsible for the accuracy of the content. Similarly, the presence of advertising neither constitutes nor implies endorsement of any of the advertised products or services by the AOA.

This complimentary copy of The Morning Brief was sent to %%email%%. View BulletinHealthcare's privacy policy.

For more information on the benefits of membership in the American Osteopathic Association, please contact the AOA at (800) 621-1773 or email touchpoint@osteopathic.org.

AOA Headquarters | 142 E. Ontario Street | Chicago, IL 60611

Copyright © 2016 by BulletinHealthcare | 11190 Sunrise Valley Drive, Suite 20 | Reston, VA 20191